CTLA4-Ig (Abatacept)
Phase 2Protein / enzyme
CTLA4-Ig (Abatacept) is one of 10 small molecule programs targeting Abnormal Glucose Tolerance. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Abnormal Glucose Tolerance
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Avandia
Alnylam PharmaceuticalsApproved
Actos
TakedaApproved
Onglyza
AstraZenecaApproved
Glucophage
EMD SeronoApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Glucophage
Boehringer IngelheimPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 2
PBI4050
LLiminal BioSciences Ltd.
Phase 2
CTLA4-Ig (Abatacept)
NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CTLA4-Ig (Abatacept). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details